Welcome to our dedicated page for KIORA PHARMACEUTICALS SEC filings (Ticker: KPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kiora Pharmaceuticals filings document a clinical-stage ophthalmology issuer focused on small-molecule programs for retinal disease. Current disclosures cover results of operations and financial condition, research-and-development progress for KIO-301 and KIO-104, collaboration reimbursements, and clinical or regulatory updates tied to the company’s development pipeline.
Material-event reports also record securities purchase agreements, common stock, pre-funded warrants and Tranche A warrants issued in private placements, along with executive changes. Proxy materials address board governance, executive compensation, equity awards, shareholder voting matters and related risk-factor disclosures for a Nasdaq-listed Delaware corporation.
Kiora Pharmaceuticals entered into a private placement with institutional investors Perceptive Advisors and ADAR1 Capital Management, raising $5.0 million upfront and providing up to an additional $19.0 million in potential warrant exercise proceeds. The deal includes 438,471 common shares, pre-funded warrants for 1,527,711 shares, and Tranche A-1 and A-2 warrants for up to 9,830,909 additional shares at an exercise price of $1.94 per share. Warrants are immediately exercisable and have milestone-based terms tied to strategic transactions and completion of Phase 3 trial enrollment. The securities were issued under Regulation D exemptions and will later be registered for resale under a planned registration statement.
Kiora Pharmaceuticals CFO Melissa Tosca reported a routine tax-related share disposition. On April 1, 2026, 929 shares of Kiora Pharmaceuticals common stock were delivered at $1.95 per share to pay an exercise price or tax liability. After this tax-withholding disposition, Tosca directly holds 26,975 shares of common stock, indicating the transaction affected only a small portion of her position and was not an open-market sale.
Kiora Pharmaceuticals Chief Development Officer Eric Joseph Daniels reported a tax-related share disposition. On the transaction date, 929 shares of Kiora Pharmaceuticals common stock were withheld at $1.95 per share to cover tax obligations. After this non-open-market tax-withholding disposition, Daniels directly held 31,741 shares of common stock.
Kiora Pharmaceuticals President and CEO Brian M. Strem reported a tax-related share disposition. On April 1, 2026, he transferred 1,906 shares of Common Stock at $1.95 per share to cover taxes by delivering shares instead of cash. After this tax-withholding disposition, he directly holds 60,692 shares of Kiora common stock. This was not an open-market sale or purchase but a routine mechanism tied to equity compensation.
Kiora Pharmaceuticals announced that Chief Development Officer Eric J. Daniels, M.D., MBA will resign effective April 17, 2026 to pursue another opportunity. The company stated his departure is not due to any disagreement over operations, policies, or practices and has begun a search for his successor.
Kiora emphasized continued progress in its retinal disease pipeline. In the ABACUS-2 Phase 2 trial of KIO-301, a planned safety review allowed enrollment of remaining patients in the 50µg dose cohort and cleared initiation of the 100µg cohort. In the KLARITY Phase 2 trial of KIO-104, all planned safety checkpoints have been cleared and patient enrollment is ongoing.
Kiora Pharmaceuticals reported a net loss of $10.8 million for 2025, compared with net income of $3.6 million in 2024, mainly because 2024 included $16.0 million of collaboration revenue and 2025 recorded a $4.6 million in-process R&D impairment related to KIO-104.
Revenue was zero in 2025, while operating expenses rose as R&D increased to $10.8 million with two Phase 2 trials underway and G&A reached $5.7 million. Kiora ended 2025 with $17.1 million in cash, cash equivalents and short-term investments plus $3.5 million in receivables and projects its cash runway into late 2027.
Pipeline progress included advancing KIO-301 and KIO-104 into active Phase 2 studies in retinal diseases and signing an option agreement with Senju Pharmaceutical with potential value of up to $110 million plus royalties, alongside continued work on the KIO-300 ion-channel modulator platform.
Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on therapies for retinal diseases. Its lead candidate, KIO-301, is a small-molecule “photoswitch” being developed for late-stage retinitis pigmentosa and other inherited retinal dystrophies. A Phase 1b trial showed safety and vision-related improvements, and a 36‑patient Phase 2 ABACUS‑2 trial in RP is enrolling under a global co-development agreement with Théa Open Innovation, which funds all KIO‑301 R&D.
The company is also advancing KIO-104, an intravitreal DHODH inhibitor for retinal inflammation such as diabetic macular edema and posterior non‑infectious uveitis, with a Phase 2 KLARITY trial dosing patients. A topical DHODH inhibitor, KIO‑101, is being positioned for partnering in ocular manifestations of autoimmune diseases. Kiora reported a $10.8 million net loss for the year ended December 31, 2025, versus net income of $3.6 million in 2024, and held $17.1 million in cash and short-term investments, which it expects to fund operations into late 2027. As of March 21, 2026, there were 3,950,628 shares of common stock outstanding.
Kiora Pharmaceuticals Chief Development Officer Eric Joseph Daniels reported a small tax-related share disposition. On March 3, 2026, he transferred 238 shares of common stock at $2.02 per share to satisfy tax withholding obligations. After this transaction, he directly held 26,137 common shares.
Kiora Pharmaceuticals President and CEO Brian M. Strem reported a tax-related stock transaction. On March 3, 2026, he disposed of 238 shares of common stock at $2.02 per share as a tax-withholding disposition, a method of paying tax obligations using shares. After this transaction, he directly owned 45,865 common shares.
Kiora Pharmaceuticals Inc. received an amended Schedule 13G from Rosalind Advisors Inc., Rosalind Master Fund L.P., and portfolio managers Steven Salamon and Gilad Aharon reporting beneficial ownership tied to warrants for up to 464,676 common shares, or 9.9% of the company based on 3,677,935 shares outstanding as of November 5, 2025. These shares are issuable upon exercise of warrants that include a 9.99% beneficial ownership blocker, so as of the December 31, 2025 event date the reporting persons state they could not exercise the warrants. The filers characterize the position as held in the ordinary course of business and state it is not for the purpose of changing or influencing control.